PharmiWeb.com - Global Pharma News & Resources
11-Dec-2018

Dexcom Donates $25,000 to Beyond Type 1

Dexcom Donates $25,000 to Beyond Type 1 Social media campaign #NoMoreFingerpricks raises funds and awareness for diabetes research

PR Newswire

SAN DIEGO, Dec. 11, 2018

SAN DIEGO, Dec. 11, 2018 /PRNewswire/ -- Last month Dexcom, the leader in Continuous Glucose Monitoring (CGM) for patients with diabetes, launched a social media campaign on November 1 which reached millions of people around the world and raised $25,000 for diabetes advocacy and research. For every photo or video posted to Facebook and Instagram using the hashtag #NoMoreFingerpricks, Dexcom committed to donating $1 to Beyond Type 1, a diabetes nonprofit working to educate, advocate and cure Type 1 diabetes.

"We're grateful for the revolutionary new technology that is now available to people with Type 1 diabetes," said Thom Scher, Beyond Type 1 CEO. "It was an inspiring experience to celebrate National Diabetes Awareness Month with Dexcom who is on the forefront of innovation in diabetes technology. This generous donation will help our organization continue to provide critical resources and support to the diabetes community."

In addition, today Dexcom released a hidden camera video showing the shocked reactions of people asked to prick their finger before eating, a task that most people with diabetes do more than eight times per day to check their glucose levels. The video is part of the company's national #NoMoreFingerpricks campaign to raise critical awareness about the complexity and seriousness of diabetes and to advocate for innovative technologies like CGM to become the standard in patient care.

"We filmed this video to show the world the unnecessary painfulness of fingerpricks many people with diabetes do every day," said Kevin Sayer, president and CEO of Dexcom. "With almost 1.5 million people in the United States living with Type 1 diabetes, it is critical that healthcare providers talk to their patients about CGM and other innovative diabetes management technologies that can improve the health and quality of life for people with diabetes."

Dexcom and Beyond Type 1 also released a survey which shows there is low awareness of CGM among people with Type 1 diabetes, despite the fact CGM eliminates painful fingerpricks, increases time in target glucose range, lowers A1C, decreases hypoglycemia and improves overall quality of life for people with diabetes.1-5

About Beyond Type 1
Founded in 2015, Beyond Type 1 is leveraging the power of social media and technology, changing what it means to live with a chronic disease. By educating the global community about this autoimmune disease, as well as providing resources and supporting those living with Type 1 diabetes, Beyond Type 1 is bridging the gap from diagnosis to cure, empowering people to live well today and funding a better tomorrow. www.beyondtype1.org.

About Dexcom, Inc.
Dexcom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com.

For more information, please contact Olivia Aulicino, hello@beyondtype1.org.

1. Šoupal J, Petruželková L, Fleka M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.
2. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomised Clinical Trial. JAMA. 2017;317(4):371-378.
3. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomised Clinical Trial. JAMA. 2017;317(4):379-387.
4. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2017.
5. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018.

 

View original content:http://www.prnewswire.com/news-releases/dexcom-donates-25-000-to-beyond-type-1--300762797.html

SOURCE Beyond Type 1

Editor Details

Last Updated: 11-Dec-2018